Spots Global Cancer Trial Database for nsabp
Every month we try and update this database with for nsabp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum | NCT00346099 | Rectal Cancer Neoplasm Metast... | Panitumumab wit... Panitumumab wit... | 18 Years - | NSABP Foundation Inc | |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | NCT02236000 | Breast Cancer | Neratinib T-DM1 | 18 Years - | NSABP Foundation Inc | |
| BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | NCT00625898 | Breast Cancer | Docetaxel Trastuzumab Carboplatin Bevacizumab 5-Fluorouracil Epirubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | NCT00052169 | Breast Neoplasm... | ZD1839 in combi... | 18 Years - | NSABP Foundation Inc | |
| Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | NCT00365417 | Breast Cancer | Bevacizumab Doxorubicin Cyclophosphamid... Capecitabine Docetaxel | 18 Years - | NSABP Foundation Inc | |
| Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | NCT00314353 | Colorectal Neop... | Bevacizumab Oxaliplatin Capecitabine Irinotecan | 18 Years - | NSABP Foundation Inc | |
| Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | NCT00464646 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Trastuzumab Bevacizumab | 18 Years - | NSABP Foundation Inc | |
| Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | NCT03102047 | Rectal Cancer | durvalumab | 18 Years - | NSABP Foundation Inc | |
| A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer | NCT00378313 | Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IV Breast... Breast Cancer Locally Advance... | gemcitabine, ep... | 18 Years - | NSABP Foundation Inc | |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | NCT03412643 | HER2-negative B... | Doxorubicin Cyclophosphamid... Weekly Paclitax... Trastuzumab Pertuzumab Celcuity CELx H... | 18 Years - | NSABP Foundation Inc | |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | NCT00052169 | Breast Neoplasm... | ZD1839 in combi... | 18 Years - | NSABP Foundation Inc | |
| A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer | NCT00378313 | Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IV Breast... Breast Cancer Locally Advance... | gemcitabine, ep... | 18 Years - | NSABP Foundation Inc | |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | NCT00052169 | Breast Neoplasm... | ZD1839 in combi... | 18 Years - | NSABP Foundation Inc | |
| Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum | NCT00346099 | Rectal Cancer Neoplasm Metast... | Panitumumab wit... Panitumumab wit... | 18 Years - | NSABP Foundation Inc | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer | NCT02664077 | Stage III (IIIB... | Regorafenib Placebo | 18 Years - | NSABP Foundation Inc | |
| Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | NCT00464646 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Trastuzumab Bevacizumab | 18 Years - | NSABP Foundation Inc | |
| Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | NCT03626922 | Metastatic Colo... | Pembrolizumab Pemetrexed Oxaliplatin Dexamethasone Folic Acid Vitamin B-12 | 18 Years - | NSABP Foundation Inc | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | NCT00486668 | Invasive Breast... | doxorubicin cyclophosphamid... paclitaxel trastuzumab lapatinib | 18 Years - | NSABP Foundation Inc | |
| A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | NCT00803647 | Metastatic Colo... | cetuximab 5-FU oxaliplatin leucovorin | 18 Years - | NSABP Foundation Inc | |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | NCT03412643 | HER2-negative B... | Doxorubicin Cyclophosphamid... Weekly Paclitax... Trastuzumab Pertuzumab Celcuity CELx H... | 18 Years - | NSABP Foundation Inc | |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | NCT01889680 | Colorectal Canc... Metastatic Colo... | 5-FU LV ziv-aflibercept mFOLFOX6 | 18 Years - | NSABP Foundation Inc | |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | NCT01889680 | Colorectal Canc... Metastatic Colo... | 5-FU LV ziv-aflibercept mFOLFOX6 | 18 Years - | NSABP Foundation Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
